02/11/2017 - 09:07 StockMarketWire
ImmuPharma is on track to report top line results from its 52-week, randomised, double-blinded, phase III clinical trial of ...
02/11/2017 - 07:00 RNS
RNS Number: 3263V Immupharma PLC 02 November 2017 2 November 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinic...
16/10/2017 - 14:29 RNS
RNS Number: 7306T Immupharma PLC 16 October 2017 TR-1: S tandard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma Plc 213800VZKGHXC7VUS895 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK iss...
04/10/2017 - 06:35 StockMarketWire
ImmuPharma has announced the completion of the sharing agreement entered into with Lanstead Capital in February 20...
|19-10-10||Update on Phase IIa Clinical||RNS|
|11-10-10||Additional Listing and Total||RNS|
|11-10-10||Notification of major interes||RNS|
|07-10-10||Hybridan's Small Cap Wrap||Hybridan|
|28-09-10||Notification of Interim Resul||RNS|
|01-07-10||Hybridan's Small Cap Wrap||Hybridan|
|27-05-10||Hybridan's Small Cap Wrap||Hybridan|
|20-05-10||Hybridan's Small Cap Wrap - 20-05-10||Hybridan|
|17-10-09||Hybridan's Small Cap Wrap||Hybridan|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment